



PRESS RELEASE

Spinomix Granted New US Patents for its MagPhase Core Technology

- Automated sample preparation platform based on magnetic beads and microfluidics
- Robust and highly flexible automation brought to every laboratory bench
- Offers new avenues in assay processing for life science research and diagnostics
- Company in discussions with commercial partners and in process of raising new funds

Lausanne, Switzerland – October 15, 2014 – Spinomix SA a Swiss technology platform company providing innovative sample processing solutions to the life sciences sector, today announced the issuance of two US Patents number US 8,585,279 and US 8,870,446 relating to the manipulation and mixing of magnetic particles in microfluidics environments.

Spinomix's proprietary technology MagPhase™ has also been granted protection in China and Japan and is in its final granting stages in Europe. These highly strategic patents raise the company's MagPhase™ US granted patent portfolio to three patents; three others are still pending approval.

“This new patent grant is of great strategic importance for Spinomix since it confirms the originality of our method and its capability of leveraging the great applications possible with magnetic beads based assays and their easy automation using microfluidic based systems,” said **Amar Rida, Founder and Chief Technology Officer of Spinomix**. “Our company is continuously committed to innovation in order to provide the marketplace with novel solutions capable of shortening the path between sample collection and results analysis.”

Although magnetic beads technology has been around since the mid 1970s, the uniqueness of the company's MagPhase™ technology is in the innovative way of homogeneously handling these beads in connection with fluids handling in microfluidics based systems, thus enhancing bioassays efficiency and opening new fields for sample processing automation. The company's goal with MagPhase™ is to bring affordable and flexible automation to every laboratory bench. The technology is being developed for life science research as well as applications which are critical for treatment decisions such as circulation tumour nucleic acids for cancer diagnosis or cell isolation in regenerative medicine.

“Our vision is to expand our microfluidics cartridges to all of the currently available applications of magnetic beads such as protein purification, cell isolation and others. We are already applying our technology to nucleic acid purification, a market estimated to be well over one billion dollars,” said **Spinomix Chief Executive Officer Nasri Nahas**. “Spinomix is well on its way to becoming a sustainable business, supported by discussions with major market players to bring our products to market.”

About MagPhase™

MagPhase™ brings seamless automation of complex analytical procedures to every laboratory bench. It combines in a unique system the proven industry standard magnetic beads technology with the miniaturization brought by microfluidics systems. MagPhase™ provides users with both high analytical performance and unmatched automation-driven flexibility and efficiency, thus enabling them to explore new avenues in assay processing for life science research and diagnostics. The MagPhase™ technology can vastly improve analysis wherever magnetic beads are being used today. It allows the transfer of all existing magnetic beads applications onto an easy to use low cost disposable cartridges-based system.

About Spinomix SA

Spinomix is a Swiss technology platform company providing innovative sample processing solutions to the life sciences sector. Based at the Ecole Polytechnique Fédérale de Lausanne (EPFL), the company is building the new gold standard for sample processing of biochemical substances. Its products capture and extract samples at a quality and efficiency far superior to current practice, thus enabling more efficient diagnostics. The company's main focus is on applications which are critical for treatment decisions in a variety of human diseases. Other applications target markets such as animal health and food safety.

Spinomix' products **MagPhase™** and **FibroTrap™** improve the sensitivity and time taken to obtain meaningful results from samples that are highly heterogeneous and notoriously difficult to analyse. (e.g. blood, urine, swabs and food matrices). The company is conducting validation programmes of these products with key market players in research and industry with the goal of developing partnerships for their commercialisation.

Our talented team has proven to be successful working at the interface between industry and academia and we benefit from a renowned Board of Directors with extensive expertise in our technologies, industry and target markets.

Further information is available at our website www.spinomix.com

Contact

Spinomix SA
Nasri Nahas CEO
contact@spinomix.com
+41 (0) 21 693 92 50

Media

Nick Miles
Cabinet Privé de Conseils
Geneva, Switzerland
miles@cpc-pr.com
+41 (0) 22 321 45 40
+41 (0) 79 678 76 26

Edward Agne
Communications Strategy Group
Cambridge, Mass, USA
edagne@comstratgroup.com
+1(0) 781 631 3117
+1(0) 781 888 0099